<DOC>
	<DOCNO>NCT02288091</DOCNO>
	<brief_summary>This single center , open label , 12-week study inosine treatment . Inosine treatment lead increase level urate ( uric acid ) blood . The primary objective study determine safety tolerability oral administration inosine . Secondary study objective include measurement biomarkers oxidative stress damage response inosine treatment .</brief_summary>
	<brief_title>A Pilot Study Inosine ALS</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) fatal , neurodegenerative disease cure . Multiple line evidence implicate oxidative stress pathophysiology ALS . Urate ( uric acid ) endogenous antioxidant system , urate may serve major defense oxidative stress . Urate emerge promising neuro-protectant therapeutic target base convergent epidemiological , laboratory , clinical data multiple neurodegenerative disease , notably Parkinson 's disease ( PD ) . In PD , urate elevation pursue potential therapy administration inosine , urate precursor available over-the-counter supplement . Administration inosine result predictable elevation urate level show safe well tolerate PD . Analysis ALS databases reveal high urate level independent predictor slow progression prolong survival ALS . However , whether elevate urate people ALS would result good outcome unknown . As first step towards development inosine potential treatment ALS , study test whether inosine administration ALS safe correlate change level biomarkers oxidative stress damage ( biomarkers intend biological effect ) . The primary outcome measure safety , measure adverse event clinically meaningful change vital sign , physical examination , standard clinical laboratory test , tolerability , define ability subject complete entire 12-week study . The secondary objective study quantify effect treatment biomarkers oxidative damage stress . An exploratory objective study measure whether change biomarkers different people bulbar-onset ALS compare people limb-onset ALS . This study conduct people meet El Escorial criterion possible , laboratory-supported probable , probable , definite criterion diagnosis ALS . At screening , eligible individual must least 18 year old must provide write informed consent prior screen . Subjects stable dose riluzole take riluzole , woman child-bearing age screen eligible inclusion long meet specific protocol requirement . Study participant administer oral inosine daily . The dose inosine titrate obtain serum urate level 7 - 8 mg/dL . Study participant remain treatment Week 12 visit . Each participant also Week 16 Follow-up Telephone Interview assess adverse event ( AEs ) , change concomitant medication administer ALSFRS-R .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Age 18 year old . 2 . Sporadic familial ALS diagnose possible , laboratorysupported probable , probable , definite define revise El Escorial criterion ( Appendix 1 ) . 3 . Capable provide informed consent follow trial procedure . 4 . Serum urate &lt; 5.5 mg/dl screening ( i.e . population median serum urate level ) . 5 . Willingness undergo magnetic resonance spectroscopy ( MRS ) Baseline Week 12 study . 6 . Women must able become pregnant ( e.g . post menopausal , surgically sterile , use adequate birth control method ) duration study 3 month study completion . Adequate contraception include : abstinence , hormonal contraception ( oral contraception , implanted contraception , inject contraception hormonal ( patch contraceptive ring , example ) contraception ) , intrauterine device ( IUD ) place â‰¥ 3 month , barrier method conjunction spermicide , another adequate method . 1 . History urolithiasis . 2 . Urine pH &lt; 5.5 screening ( acidic urine major determinant uric acid urolithiasis ) . 3 . Urate crystalluria Screening . 4 . History gout . 5 . History stroke myocardial infarction . 6 . History symptomatic coronary artery disease ( e.g . angina pectoris ) symptomatic peripheral arterial disease within 1 year prior Screening . 7 . Symptomatic congestive heart failure document ejection fraction 45 % . 8 . Poorly control arterial hypertension ( SBP &gt; 160mmHg DBP &gt; 100mmHg Screening ) . 9 . Contraindications undergo magnetic resonance spectroscopy ( MRS ) Baseline Week 12 study history claustrophobia , inability lie flat approximately one hour , metal implant ( metal pin plate , extensive nonremovable dental work , cerebral aneurysm clip , pacemaker ) . 10 . Women pregnant lactating . 11 . The presence unstable psychiatric disease , cognitive impairment , dementia would impair ability subject provide inform consent , accord PI judgment , history active substance abuse within prior year . 12 . Anything , opinion investigator , would place subject increase risk preclude subject 's full compliance completion study . 13 . Use follow within 30 day prior Screening : inosine , allopurinol , probenecid , 300mg vitamin C daily ( note subject may take standard multivitamin one tablet capsule daily ) . Use thiazides permissible long subject stable dose 1 week prior Screening . 14 . Known hypersensitivity intolerability inosine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>Inosine</keyword>
	<keyword>Uric acid</keyword>
	<keyword>Urate</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Oxidative damage</keyword>
	<keyword>proof-of-concept</keyword>
</DOC>